INC280 single agent
CINC280B2201
Phase 1 small_molecule terminated
Quick answer
INC280 single agent for Non-Small Cell Lung Cancer is a Phase 1 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Non-Small Cell Lung Cancer
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated